SCHEMBL3305997

SCHEMBL3305997

FC(F)(F)c1cc(NC(=S)NCc2cccc(Cl)c2)cc(C(F)(F)F)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.74
MAX P61244 1/20 0.74
MAPT P10636 7/20 0.66
MEN1 O00255 6/20 0.66
KMT2A Q03164 6/20 0.66
NPSR1 Q6W5P4 2/20 0.66
HTT P42858 2/20 0.66
HPGD P15428 4/20 0.63
LMNA P02545 4/20 0.60
MAOB P27338 2/20 0.60
PLA2G1B P04054 1/20 0.60
ATG4B Q9Y4P1 1/20 0.60
CYP19A1 P11511 1/20 0.59
ALDH1A1 P00352 5/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C19 P33261 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3305182 0.88 NPC1 (0.60) MYCMAXMAPTMEN1KMT2A
SCHEMBL3300939 0.85 MAPT (0.79) MYCMAXMAPTMEN1KMT2A
SCHEMBL3299625 0.85 MYC (1.00) MYCMAXMAPTMEN1KMT2A
SCHEMBL3302805 0.83 MYC (0.67) MYCMAXMAPTMEN1KMT2A
SCHEMBL14434549 0.81 CYP19A1 (0.88) MAPTMEN1KMT2ANPSR1HPGD
SCHEMBL5450570 0.81 MAOB (0.83) MAPTMEN1KMT2ANPSR1HPGD
SCHEMBL3301650 0.80 MAPT (0.66) MYCMAXMAPTMEN1KMT2A
SCHEMBL3298774 0.79 ALDH1A1 (0.78) MYCMAXMAPTMEN1KMT2A
SCHEMBL3300342 0.78 MYC (0.67) MYCMAXMAPTMEN1KMT2A
SCHEMBL3304422 0.78 MYC (0.67) MYCMAXMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS TST, TPX2, TPMT MYC 1961/4885MAX 2281/4885MAPT 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.